- Home
- PANW vs SNY Comparison
PANW vs SNY Comparison
Compare PANW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- SNY
- Stock Information
- Founded
- PANW 2005
- SNY 1994
- Country
- PANW United States
- SNY France
- Employees
- PANW N/A
- SNY N/A
- Industry
- PANW Computer peripheral equipment
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- PANW Technology
- SNY Health Care
- Exchange
- PANW Nasdaq
- SNY Nasdaq
- Market Cap
- PANW 124.9B
- SNY 116.1B
- IPO Year
- PANW 2012
- SNY N/A
- Fundamental
- Price
- PANW $218.27
- SNY $50.94
- Analyst Decision
- PANW Buy
- SNY Buy
- Analyst Count
- PANW 43
- SNY 4
- Target Price
- PANW $216.33
- SNY $61.50
- AVG Volume (30 Days)
- PANW 4.6M
- SNY 2.8M
- Earning Date
- PANW 11-19-2025
- SNY 10-24-2025
- Dividend Yield
- PANW N/A
- SNY 3.14%
- EPS Growth
- PANW N/A
- SNY 105.93
- EPS
- PANW 1.60
- SNY 8.67
- Revenue
- PANW $9,221,500,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- PANW $16.29
- SNY $1.40
- Revenue Next Year
- PANW $13.42
- SNY $6.67
- P/E Ratio
- PANW $136.42
- SNY $5.87
- Revenue Growth
- PANW 14.87
- SNY N/A
- 52 Week Low
- PANW $144.15
- SNY $44.62
- 52 Week High
- PANW $223.61
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- PANW 61.36
- SNY 58.82
- Support Level
- PANW $216.00
- SNY $50.54
- Resistance Level
- PANW $223.61
- SNY $51.64
- Average True Range (ATR)
- PANW 4.22
- SNY 0.69
- MACD
- PANW 0.16
- SNY 0.11
- Stochastic Oscillator
- PANW 73.60
- SNY 68.02
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.